MX349754B - Metodo para la administracion de 4-((1r,3s)-6-cloro-3-fenil-indan- 1-il)-1,2,2-trimetil-piperazina y de sus sales en el tratamiento de esquinozofrenia. - Google Patents
Metodo para la administracion de 4-((1r,3s)-6-cloro-3-fenil-indan- 1-il)-1,2,2-trimetil-piperazina y de sus sales en el tratamiento de esquinozofrenia.Info
- Publication number
- MX349754B MX349754B MX2013014978A MX2013014978A MX349754B MX 349754 B MX349754 B MX 349754B MX 2013014978 A MX2013014978 A MX 2013014978A MX 2013014978 A MX2013014978 A MX 2013014978A MX 349754 B MX349754 B MX 349754B
- Authority
- MX
- Mexico
- Prior art keywords
- indan
- piperazine
- trimethyl
- chloro
- phenyl
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- BYPMJBXPNZMNQD-PZJWPPBQSA-N Zicronapine Chemical compound C1C(C)(C)N(C)CCN1[C@H]1C2=CC(Cl)=CC=C2[C@H](C=2C=CC=CC=2)C1 BYPMJBXPNZMNQD-PZJWPPBQSA-N 0.000 title 1
- 201000000980 schizophrenia Diseases 0.000 title 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 abstract 1
- 108091005479 5-HT2 receptors Proteins 0.000 abstract 1
- 101150049660 DRD2 gene Proteins 0.000 abstract 1
- 108090000511 Dopamine D1 Receptors Proteins 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003442 weekly effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161498653P | 2011-06-20 | 2011-06-20 | |
| DKPA201100465 | 2011-06-20 | ||
| PCT/EP2012/061779 WO2012175531A1 (en) | 2011-06-20 | 2012-06-20 | Method of administration of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013014978A MX2013014978A (es) | 2014-04-10 |
| MX349754B true MX349754B (es) | 2017-08-11 |
Family
ID=58794324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013014978A MX349754B (es) | 2011-06-20 | 2012-06-20 | Metodo para la administracion de 4-((1r,3s)-6-cloro-3-fenil-indan- 1-il)-1,2,2-trimetil-piperazina y de sus sales en el tratamiento de esquinozofrenia. |
Country Status (23)
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7402400B2 (en) | 2001-07-03 | 2008-07-22 | Regents Of The University Of California | Mammalian sweet taste receptors |
| EP1230256A4 (en) | 1999-11-17 | 2005-03-09 | Mendel Biotechnology Inc | GENES OF PLANT DEVELOPMENT |
| US6458538B1 (en) | 1999-12-14 | 2002-10-01 | Ptc Therapeutics, Inc. | Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay |
| TW201006846A (en) | 2000-03-07 | 2010-02-16 | Senomyx Inc | T1R taste receptor and genes encidung same |
| EP1406483A4 (en) | 2000-08-22 | 2005-05-25 | Mendel Biotechnology Inc | GENE FOR CHANGING THE PROPERTIES OF PLANTS |
| US7045283B2 (en) | 2000-10-18 | 2006-05-16 | The Regents Of The University Of California | Methods of high-throughput screening for internalizing antibodies |
| US7883856B2 (en) | 2001-04-05 | 2011-02-08 | Senomyx Inc. | Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators |
| WO2003001876A2 (en) | 2001-06-26 | 2003-01-09 | Senomyx, Inc. | T1r hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds |
| US7871619B2 (en) | 2001-11-30 | 2011-01-18 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| AU2003304411A1 (en) | 2002-08-01 | 2005-03-07 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| WO2004016733A2 (en) | 2002-08-16 | 2004-02-26 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
| ATE539158T1 (de) | 2002-09-18 | 2012-01-15 | Mendel Biotechnology Inc | Polynukleotide und polypeptide in pflanzen |
| EP2319524B1 (en) | 2003-05-30 | 2013-08-21 | Agensys, Inc. | Prostate stem cell antigen (PSCA) variants and subsequences thereof |
| EP2369348A1 (en) | 2003-11-07 | 2011-09-28 | Ciphergen Biosystems, Inc. | Biomarkers for Alzheimer's disease |
| WO2005060739A1 (en) | 2003-12-24 | 2005-07-07 | G2 Inflammation Pty Ltd | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar |
| EP1734996B1 (en) | 2004-04-02 | 2013-05-22 | The Regents of The University of California | Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin |
| US7939251B2 (en) | 2004-05-06 | 2011-05-10 | Roche Molecular Systems, Inc. | SENP1 as a marker for cancer |
| EP1753871B1 (en) | 2004-05-28 | 2015-07-15 | Agensys, Inc. | Antibodies and related molecules that bind to psca proteins |
| DK2453024T3 (en) | 2004-06-21 | 2018-02-12 | Univ Leland Stanford Junior | Genes and conduits that are differentially expressed in bipolar disorder and / or major depressive disorder |
| US7850960B2 (en) | 2004-12-30 | 2010-12-14 | University Of Washington | Methods for regulation of stem cells |
| US7700738B2 (en) | 2005-01-27 | 2010-04-20 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| EP3300739A3 (en) | 2005-03-31 | 2018-07-18 | Agensys, Inc. | Antibodies and related molecules that bind to 161p2f10b proteins |
| WO2007010394A2 (en) | 2005-07-19 | 2007-01-25 | Stemgen S.P.A. | Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps |
| CN101605810B (zh) | 2005-10-20 | 2013-07-17 | 塞诺米克斯公司 | 嵌合的人甜味-鲜味和鲜味-甜味受体 |
| EP1945261A4 (en) | 2005-11-07 | 2010-05-12 | Scripps Research Inst | COMPOSITIONS AND METHODS FOR CONTROLLING THE SPECIFICITY OF TISSUE FACTOR SIGNALING |
| US20090233842A1 (en) | 2005-11-12 | 2009-09-17 | Prtzker Neuropsychiatric Research Fund Llc | Fgf2-related methods for diagnosing and treating depression |
| CN103301475B (zh) | 2005-12-28 | 2016-08-03 | 斯克里普斯研究所 | 药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用 |
| AU2007227195A1 (en) | 2006-03-21 | 2007-09-27 | The Regents Of The University Of California | N-cadherin and Ly6 E: targets for cancer diagnosis and therapy |
| US20100278821A1 (en) | 2006-03-21 | 2010-11-04 | The Regents Of The University Of California | N-cadherin: target for cancer diagnosis and therapy |
| US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
| EP2423332A1 (en) | 2006-08-25 | 2012-02-29 | Oncotherapy Science, Inc. | Prognostic markers and therapeutic targets for lung cancer |
| CA2661633A1 (en) | 2006-09-06 | 2008-03-13 | The Regents Of The University Of California | Molecular diagnosis and classification of malignant melanoma |
| EP2095100B1 (en) | 2006-11-22 | 2016-09-21 | President and Fellows of Harvard College | Method of operating a nanowire field effect transistor sensor |
| IN2009KN04568A (cg-RX-API-DMAC7.html) | 2007-06-01 | 2015-08-28 | Univ Princeton | |
| EP2522752B1 (en) | 2007-08-13 | 2014-04-02 | Baxter International Inc. | IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease |
| MX2010001995A (es) | 2007-08-21 | 2010-06-09 | Senomyx Inc | Identificacion de receptores t2r humanos que responden a compuestos amargos que provocan el sabor amargo en composiciones, y uso de los mismos en ensayos para identificar compuestos que inhiben (bloquean) sabor amargo en composiciones y uso de los mi |
| US7858759B2 (en) | 2007-10-04 | 2010-12-28 | Zymogenetics, Inc. | Anti-zB7H6 antibody-drug conjugates |
| WO2009055487A1 (en) | 2007-10-22 | 2009-04-30 | The Regents Of The University Of California | Biomarkers for prenatal diagnosis of congenital cytomegalovirus |
| US8415361B2 (en) | 2007-11-09 | 2013-04-09 | The Salk Institute For Biological Studies | Use of TAM receptor inhibitors as antimicrobials |
| WO2009117439A2 (en) | 2008-03-17 | 2009-09-24 | The Scripps Research Institute | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
| CA2721980C (en) | 2008-04-21 | 2017-01-03 | The Regents Of The University Of California | Selective high-affinity poly dentate ligands and methods of making such |
| JP2011529708A (ja) | 2008-08-04 | 2011-12-15 | ユニバーシティ オブ マイアミ | 自然免疫応答の調節因子ｓｔｉｎｇ（インターフェロン遺伝子の刺激因子） |
| US20110287026A1 (en) | 2008-09-23 | 2011-11-24 | President And Fellows Of Harvard College | Sirt4 and uses thereof |
| EP3260123A1 (en) | 2008-11-06 | 2017-12-27 | University of Miami | Role of soluble upar in the pathogenesis of proteinuric kidney disease |
| EP2352847B1 (en) | 2008-11-10 | 2014-01-08 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Gene signature for predicting prognosis of patients with solid tumors |
| SG196784A1 (en) | 2008-12-03 | 2014-02-13 | Scripps Research Inst | Stem cell cultures |
| SG172160A1 (en) | 2008-12-17 | 2011-07-28 | Scripps Research Inst | Generation and maintenance of stem cells |
| DK2411410T3 (en) | 2009-03-27 | 2015-09-07 | Gojo Ind Inc | Compositions and methods for screening and use of compounds which counteract the track-surface interactions |
| US10087252B2 (en) | 2009-07-24 | 2018-10-02 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with αvβ5 integrin |
| MX2012001746A (es) | 2009-08-14 | 2012-03-21 | Univ California | Metodos de diagnostico y tratamiento de autismo. |
| WO2011022638A1 (en) | 2009-08-20 | 2011-02-24 | Transposagen Biopharmaceuticals, Inc. | Trp inhibitors and uses thereof |
| WO2011038228A1 (en) | 2009-09-24 | 2011-03-31 | President And Fellows Of Harvard College | Bent nanowires and related probing of species |
| ES2365343B1 (es) | 2009-11-19 | 2012-07-10 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Uso de cd98 como marcador de receptividad endometrial. |
| WO2011094759A2 (en) | 2010-02-01 | 2011-08-04 | The Regents Of The University Of California | Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies |
| WO2012052391A1 (en) | 2010-10-19 | 2012-04-26 | Glaxo Group Limited | Polypeptide with jmjd3 catalytic activity |
| WO2012109495A1 (en) | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
| WO2012119989A2 (en) | 2011-03-04 | 2012-09-13 | Oryzon Genomics, S.A. | Methods and antibodies for the diagnosis and treatment of cancer |
| US20120301904A1 (en) | 2011-04-26 | 2012-11-29 | Prosetta Antiviral, Inc | Multiprotein assemblies |
| EP2825209B1 (en) | 2012-03-14 | 2018-08-29 | University of Central Florida Research Foundation, Inc. | Neurofibromatoses therapeutic agents and screening for same |
| EP2836482B1 (en) | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
| HK1203209A1 (en) | 2012-04-24 | 2015-10-23 | University Of Miami | Perforin 2 defense against invasive and multidrug resistant pathogens |
| CA2879542A1 (en) | 2012-07-25 | 2014-01-30 | Salk Institute For Biological Studies | Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine |
| CA2922849A1 (en) | 2012-08-31 | 2014-03-06 | Ixchel Pharma, Llc | Agents useful for treating obesity, diabetes and related disorders |
| AU2013204200B2 (en) | 2012-10-11 | 2016-10-20 | Brandeis University | Treatment of amyotrophic lateral sclerosis |
| US20140120116A1 (en) | 2012-10-26 | 2014-05-01 | The Chinese University Of Hong Kong | Treatment of cancer using smad3 inhibitor |
| WO2014124339A2 (en) | 2013-02-07 | 2014-08-14 | The Regents Of The University Of California | Use of translational profiling to identify target molecules for therapeutic treatment |
| WO2014144844A1 (en) | 2013-03-15 | 2014-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY |
| WO2015089327A1 (en) | 2013-12-11 | 2015-06-18 | Biogen Idec Ma Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
| WO2015089338A2 (en) | 2013-12-11 | 2015-06-18 | Sloan-Kettering Institute For Cancer Research | Glucocorticoid inhibitors for treatment of prostate cancer |
| WO2015136509A2 (en) | 2014-03-14 | 2015-09-17 | Genesis Theranostix Korlatolt Felelossegu Tarsasag | Diagnostic and therapeutic targets for preeclampsia and closely related complications of pregnancy |
| WO2016195982A2 (en) | 2015-06-01 | 2016-12-08 | The Penn State Research Foundation | Hepatitis b virus capsid assembly |
| EP3314260B1 (en) | 2015-06-24 | 2021-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for detecting protein-protein interactions |
| WO2018036503A1 (en) | 2016-08-25 | 2018-03-01 | The Chinese University Of Hong Kong | Fecal bacterial markers for colorectal cancer |
| CN110291084A (zh) | 2016-12-15 | 2019-09-27 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
| WO2018175324A1 (en) | 2017-03-20 | 2018-09-27 | The Broad Institute, Inc. | Compounds and methods for regulating insulin secretion |
| CA3057999A1 (en) | 2017-04-04 | 2018-10-11 | Loma Linda University | Biologic for the treatment of cancer |
| WO2019207587A1 (en) | 2018-04-26 | 2019-10-31 | Technion Research & Development Foundation Limited | A device and a method for determining cell indentation activity |
| US20210395751A1 (en) | 2018-10-31 | 2021-12-23 | The University Of Sydney | Compositions and methods for treating viral infections |
| WO2020097261A1 (en) | 2018-11-06 | 2020-05-14 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | New compositions and methods for treating beta-globinopathies |
| WO2022105835A1 (en) | 2020-11-19 | 2022-05-27 | The Chinese University Of Hong Kong | Assessing risk for colorectal adenoma recurrence by noninvasive means |
| WO2023081167A2 (en) | 2021-11-02 | 2023-05-11 | The Regents Of The University Of California | P-selectin mutants and modulation of integrin-mediated signaling |
| WO2023146807A1 (en) | 2022-01-25 | 2023-08-03 | The Regents Of The University Of California | Vegf mutants and modulation of integrin-mediated signaling |
| WO2024197185A1 (en) | 2023-03-21 | 2024-09-26 | The Broad Institute, Inc. | Methods and compositions for dissecting organelle physiology |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK55192D0 (da) | 1992-04-28 | 1992-04-28 | Lundbeck & Co As H | 1-piperazino-1,2-dihydroindenderivater |
| HRP20121010T1 (hr) | 2003-08-18 | 2013-01-31 | H. Lundbeck A/S | Trans-1(6-klor-3-fenilindan-1-il)-3,3-dimetilpiperazin |
| BRPI0510074A (pt) | 2004-04-22 | 2007-10-16 | Boehringer Ingelheim Int | composições farmacêuticas para o tratamento de distúrbios sexuais ii |
| CN103637977A (zh) * | 2005-07-18 | 2014-03-19 | 宾夕法尼亚大学理事会 | 含药植入物及其使用方法 |
| CN102065861B (zh) * | 2008-05-07 | 2013-10-16 | H.隆德贝克有限公司 | 反式-4-((1r，3s)-6-氯-3-苯基茚满-1-基)-1，2，2-三甲基哌嗪用于改善认知的用途 |
| EA201170512A1 (ru) * | 2008-10-03 | 2011-08-30 | Х. Лундбекк А/С | Композиция для перорального введения |
| AR077225A1 (es) * | 2009-06-24 | 2011-08-10 | Organon Nv | Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza |
-
2012
- 2012-06-19 TW TW101121870A patent/TWI552751B/zh not_active IP Right Cessation
- 2012-06-19 JO JOP/2012/0162A patent/JO3421B1/ar active
- 2012-06-20 CN CN201280029452.1A patent/CN103608015A/zh active Pending
- 2012-06-20 LT LTEP12729555.8T patent/LT2720698T/lt unknown
- 2012-06-20 PL PL12729555T patent/PL2720698T3/pl unknown
- 2012-06-20 AU AU2012274150A patent/AU2012274150B2/en not_active Ceased
- 2012-06-20 RS RS20181311A patent/RS57944B1/sr unknown
- 2012-06-20 WO PCT/EP2012/061779 patent/WO2012175531A1/en not_active Ceased
- 2012-06-20 RU RU2014101482A patent/RU2613177C2/ru active
- 2012-06-20 DK DK12729555.8T patent/DK2720698T3/en active
- 2012-06-20 US US14/126,499 patent/US9610287B2/en active Active
- 2012-06-20 SI SI201231436T patent/SI2720698T1/sl unknown
- 2012-06-20 KR KR1020137033338A patent/KR101900989B1/ko not_active Expired - Fee Related
- 2012-06-20 HR HRP20181684TT patent/HRP20181684T1/hr unknown
- 2012-06-20 MX MX2013014978A patent/MX349754B/es active IP Right Grant
- 2012-06-20 BR BR112013032178A patent/BR112013032178A2/pt not_active Application Discontinuation
- 2012-06-20 EP EP12729555.8A patent/EP2720698B1/en active Active
- 2012-06-20 JP JP2014516318A patent/JP6140151B2/ja active Active
- 2012-06-20 CA CA2838055A patent/CA2838055C/en not_active Expired - Fee Related
- 2012-06-20 ES ES12729555.8T patent/ES2694298T3/es active Active
- 2012-06-20 SM SM20180567T patent/SMT201800567T1/it unknown
-
2013
- 2013-12-19 ZA ZA2013/09617A patent/ZA201309617B/en unknown
- 2013-12-19 IL IL230060A patent/IL230060A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP2720698A1 (en) | 2014-04-23 |
| JP2014517050A (ja) | 2014-07-17 |
| KR20140033419A (ko) | 2014-03-18 |
| RU2613177C2 (ru) | 2017-03-15 |
| ES2694298T3 (es) | 2018-12-19 |
| TW201306840A (zh) | 2013-02-16 |
| IL230060A (en) | 2017-10-31 |
| LT2720698T (lt) | 2018-11-12 |
| HRP20181684T1 (hr) | 2018-12-14 |
| TWI552751B (zh) | 2016-10-11 |
| KR101900989B1 (ko) | 2018-09-20 |
| SI2720698T1 (sl) | 2018-12-31 |
| RU2014101482A (ru) | 2015-07-27 |
| AU2012274150A1 (en) | 2014-01-09 |
| DK2720698T3 (en) | 2018-11-26 |
| US9610287B2 (en) | 2017-04-04 |
| EP2720698B1 (en) | 2018-10-03 |
| JO3421B1 (ar) | 2019-10-20 |
| CA2838055C (en) | 2021-01-26 |
| SMT201800567T1 (it) | 2018-11-09 |
| BR112013032178A2 (pt) | 2016-12-20 |
| CN103608015A (zh) | 2014-02-26 |
| MX2013014978A (es) | 2014-04-10 |
| AU2012274150B2 (en) | 2016-10-06 |
| PL2720698T3 (pl) | 2019-01-31 |
| RS57944B1 (sr) | 2019-01-31 |
| CA2838055A1 (en) | 2012-12-27 |
| ZA201309617B (en) | 2015-04-29 |
| US20140194409A1 (en) | 2014-07-10 |
| JP6140151B2 (ja) | 2017-05-31 |
| WO2012175531A1 (en) | 2012-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX349754B (es) | Metodo para la administracion de 4-((1r,3s)-6-cloro-3-fenil-indan- 1-il)-1,2,2-trimetil-piperazina y de sus sales en el tratamiento de esquinozofrenia. | |
| MY174888A (en) | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | |
| IN2014DN09434A (cg-RX-API-DMAC7.html) | ||
| MD4538B1 (ro) | 1-Piperazino-3-fenil-indani deuteraţi pentru tratamentul schizofreniei | |
| PH12014500355A1 (en) | Lysophosphatidic acid receptor antagonists | |
| PH12014501056A1 (en) | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities | |
| MX343620B (es) | Forma polimorfica de clorhidrato de pridopidina. | |
| EA201400569A1 (ru) | Новые производные циклогексиламина, обладающие агонистической активностью по отношению к бета-2 адренергическому рецептору и антагонистической активностью по отношению к мускариновому рецептору м3 | |
| CL2013003042A1 (es) | Compuestos derivados metilamina de biciclos sustituidos, moduladores de receptores de esfingosin-1- fosfato; composicion farmaceutica; y un metodo de tratamiento para tratar enfermedades oculares, degeneracion macular, retinopatia, entre otros | |
| UA109260C2 (uk) | Хромонові похідні, спосіб їх одержання та їх терапевтичні застосування | |
| GEP201606526B (en) | 5-ht3 receptor antagonists | |
| TN2015000271A1 (en) | New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity | |
| PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
| MX2014000855A (es) | Moduladores receptores de glucagon de quinolinilo. | |
| PH12013501896A1 (en) | Use of a sprayable composition comprising ambroxol | |
| WO2012149481A8 (en) | Novel peptide inhibitors of serotonin 5-ht2c receptor:pten interaction | |
| TN2013000503A1 (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | |
| MY166773A (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | |
| CY1120838T1 (el) | Μεθοδος χορηγησης 4-((1r,3s)-6-xλωpo-3-φainyλo-inδan-1-yλo)-1,2,2-τριμεθυλο-πιπεραζινης και των αλατων αυτης στην αντιμετωπιση σχιζοφρενειας |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |